Literature DB >> 23833234

Primary vascularization of allografts governs their immunogenicity and susceptibility to tolerogenesis.

Cavit D Kant1, Yoshinobu Akiyama, Katsunori Tanaka, Susan Shea, Sarah E Connolly, Sharon Germana, Henry J Winn, Christian LeGuern, Georges Tocco, Gilles Benichou.   

Abstract

We investigated the influence of allograft primary vascularization on alloimmunity, rejection, and tolerance in mice. First, we showed that fully allogeneic primarily vascularized and conventional skin transplants were rejected at the same pace. Remarkably, however, short-term treatment of mice with anti-CD40L Abs achieved long-term survival of vascularized skin and cardiac transplants but not conventional skin grafts. Nonvascularized skin transplants triggered vigorous direct and indirect proinflammatory type 1 T cell responses (IL-2 and IFN-γ), whereas primarily vascularized skin allografts failed to trigger a significant indirect alloresponse. A similar lack of indirect alloreactivity was also observed after placement of different vascularized organ transplants, including hearts and kidneys, whereas hearts placed under the skin (nonvascularized) triggered potent indirect alloresponses. Altogether, these results suggest that primary vascularization of allografts is associated with a lack of indirect T cell alloreactivity. Finally, we show that long-term survival of vascularized skin allografts induced by anti-CD40L Abs was associated with a combined lack of indirect alloresponse and a shift of the direct alloresponse toward a type 2 cytokine (IL-4, IL-10)-secretion pattern but no activation/expansion of Foxp3(+) regulatory T cells. Therefore, primary vascularization of allografts governs their immunogenicity and tolerogenicity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23833234      PMCID: PMC3735678          DOI: 10.4049/jimmunol.1202092

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts.

Authors:  M A Williams; J Trambley; J Ha; A B Adams; M M Durham; P Rees; S R Cowan; T C Pearson; C P Larsen
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

2.  Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue.

Authors:  F G Lakkis; A Arakelov; B T Konieczny; Y Inoue
Journal:  Nat Med       Date:  2000-06       Impact factor: 53.440

3.  CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II.

Authors:  B A Pietra; A Wiseman; A Bolwerk; M Rizeq; R G Gill
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

4.  Skin allograft rejection by stable hematopoietic chimeras that accept organ allografts sill is an enigma.

Authors:  D Steinmuller
Journal:  Transplantation       Date:  2001-07-15       Impact factor: 4.939

5.  Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen.

Authors:  K M Thorstenson; A Khoruts
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

6.  Analysis of the CD40 and CD28 pathways on alloimmune responses by CD4+ T cells in vivo.

Authors:  A W Bingaman; J Ha; M M Durham; S Y Waitze; C Tucker-Burden; S R Cowan; T C Pearson; C P Larsen
Journal:  Transplantation       Date:  2001-10-15       Impact factor: 4.939

7.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.

Authors:  C P Larsen; E T Elwood; D Z Alexander; S C Ritchie; R Hendrix; C Tucker-Burden; H R Cho; A Aruffo; D Hollenbaugh; P S Linsley; K J Winn; T C Pearson
Journal:  Nature       Date:  1996-05-30       Impact factor: 49.962

8.  Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy.

Authors:  R S Lee; K Yamada; S L Houser; K L Womer; M E Maloney; H S Rose; M H Sayegh; J C Madsen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

9.  Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade.

Authors:  A Yamada; A Chandraker; T M Laufer; A J Gerth; M H Sayegh; H Auchincloss
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

10.  A role for TGFbeta and B cells in immunologic tolerance after intravenous injection of soluble antigen.

Authors:  A Valujskikh; A M VanBuskirk; C G Orosz; P S Heeger
Journal:  Transplantation       Date:  2001-08-27       Impact factor: 4.939

View more
  9 in total

1.  Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long-term graft-localized immune privilege.

Authors:  Kyle B Woodward; Hong Zhao; Pradeep Shrestha; Lalit Batra; Min Tan; Orlando Grimany-Nuno; Laura Bandura-Morgan; Nadir Askenasy; Haval Shirwan; Esma S Yolcu
Journal:  Am J Transplant       Date:  2020-01-05       Impact factor: 8.086

Review 2.  Emerging role of exosomes in allorecognition and allograft rejection.

Authors:  Bruno Gonzalez-Nolasco; Mengchuan Wang; Aurore Prunevieille; Gilles Benichou
Journal:  Curr Opin Organ Transplant       Date:  2018-02       Impact factor: 2.640

3.  Persistence of Indirect but Not Direct T Cell Xenoresponses in Baboon Recipients of Pig Cell and Organ Transplants.

Authors:  L Buhler; B M-W Illigens; O Nadazdin; A Tena; S Lee; D H Sachs; D K C Cooper; G Benichou
Journal:  Am J Transplant       Date:  2016-03-14       Impact factor: 8.086

4.  Both rejection and tolerance of allografts can occur in the absence of secondary lymphoid tissues.

Authors:  Cavit D Kant; Yoshinobu Akiyama; Katsunori Tanaka; Susan Shea; Yohei Yamada; Sarah E Connolly; Jose Marino; Georges Tocco; Gilles Benichou
Journal:  J Immunol       Date:  2014-12-22       Impact factor: 5.422

5.  The MEK Inhibitor Trametinib Suppresses Major Histocompatibility Antigen-mismatched Rejection Following Pancreatic Islet Transplantation.

Authors:  Seiichiro Tada; Takayuki Anazawa; Takero Shindo; Kei Yamane; Kenta Inoguchi; Nanae Fujimoto; Kazuyuki Nagai; Toshihiko Masui; Hideaki Okajima; Kyoichi Takaori; Shoichiro Sumi; Shinji Uemoto
Journal:  Transplant Direct       Date:  2020-08-12

6.  Donor exosomes rather than passenger leukocytes initiate alloreactive T cell responses after transplantation.

Authors:  Jose Marino; Mohamed H Babiker-Mohamed; Patrick Crosby-Bertorini; Joshua T Paster; Christian LeGuern; Sharon Germana; Reza Abdi; Mayuko Uehara; James I Kim; James F Markmann; Georges Tocco; Gilles Benichou
Journal:  Sci Immunol       Date:  2016-07-14

Review 7.  Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response.

Authors:  Ervin Ç Mingomataj; Alketa H Bakiri
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 8.  Dendritic cells and innate immunity in kidney transplantation.

Authors:  Quan Zhuang; Fadi G Lakkis
Journal:  Kidney Int       Date:  2015-01-28       Impact factor: 10.612

Review 9.  Allorecognition by T Lymphocytes and Allograft Rejection.

Authors:  Jose Marino; Joshua Paster; Gilles Benichou
Journal:  Front Immunol       Date:  2016-12-14       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.